Overview

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Atomoxetine Hydrochloride
Olanzapine